Why the study?
Does low-dose macrolide therapy reduce mortality in patients with ARDS?
Does low-dose macrolide therapy reduce mortality in patients with ARDS?
Low-dose macrolide therapy may be associated with reduced mortality in patients with ARDS.
Low-dose macrolides may be associated with lower ARDS mortality; leaves open whether RCTs are warranted.
These data together show that low-dose macrolide therapy prescribed for another reason than infection is associated with decreased mortality in patients with ARDS.
No takes yet. Share an insight, caveat, or question.
Simonis et al. (2018) studied this question.